Roche's Commitment to the Mpox Response
Roche is dedicated to aiding those fighting the mpox outbreak by ensuring access to high-quality Polymerase Chain Reaction (PCR) testing. The company has confirmed that its cobas MPXV test, along with the LightMix research use only kits, can detect the latest variants of the mpox virus. Furthermore, Roche is actively working to improve laboratory testing capacity for mpox on a global scale.
Global Health Emergency Declaration
Roche has announced its support for the international response to the mpox global health emergency through its diagnostic tests specifically developed for mpox, which was previously known as monkeypox. Mpox is a viral disease that spreads easily between individuals and from infected animals, and it has been designated a Public Health Emergency of International Concern by the World Health Organization.
Collaborations to Fight Mpox
Roche is collaborating with governments, healthcare providers, and organizations worldwide that are committed to combating the mpox outbreak. The company is working closely with its partners to enhance laboratory capacity for mpox testing globally and is providing training for laboratories across Africa at the Roche Scientific Campus.
Advancements in Diagnostic Testing
“Our commitment to supporting the global response to mpox began in 2022 when we created a range of tests to facilitate rapid and high-quality PCR testing worldwide,” stated the CEO of Roche Diagnostics. “Diagnostics play a crucial role in tackling emerging public health challenges like mpox, as they enable healthcare providers to identify infected individuals, develop effective treatment plans, and implement necessary measures.”
LightMix Modular Virus Kits
To detect the mpox virus, Roche has developed three distinct LightMix Modular Virus kits compatible with several instruments, including the LightCycler and cobas systems. These assays are designed to assist in tracking the epidemiological spread of the virus.
About the Cobas MPXV Test
The cobas MPXV test, which has received Emergency Use authorization, is an automated real-time PCR test designed to detect the virus responsible for mpox in human lesion swabs. Its dual-target approach ensures effectiveness even in the face of potential virus mutations.
Understanding the Mpox Virus
The MPXV virus, initially identified in laboratory monkeys, is believed to be transmitted from wild animals to humans or through human-to-human contact. Symptoms typically include fever, chills, headaches, muscle aches, and a painful rash that can develop into fluid-filled bumps before healing.
About Roche
Founded in 1896, Roche has evolved into the world's largest biotechnology company and a global leader in in-vitro diagnostics. The company is committed to providing innovative medicines and diagnostics that enhance health outcomes for people around the world.
Roche has also been acknowledged for its sustainability initiatives, underscoring its commitment to healthcare access and global partnerships.
Contact Information
For more information, please contact Roche Global Media Relations at +41 61 688 8888 or via email at media.relations@roche.com.
Frequently Asked Questions
What is Roche's role in the mpox outbreak?
Roche is providing diagnostic solutions and enhancing laboratory testing capacity to support global health initiatives against the mpox outbreak.
What tests has Roche developed for mpox?
Roche has created the cobas MPXV test and several LightMix Modular Virus kits for detecting the mpox virus.
How does mpox spread?
Mpox spreads easily between individuals and can also be transmitted from infected animals to humans.
What are the symptoms of mpox?
Symptoms of mpox include fever, chills, headaches, muscle aches, and a painful rash that can turn into fluid-filled bumps.
How long has Roche been in operation?
Roche was established in 1896 and has since become a prominent leader in biotechnology and diagnostics.
